BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 25, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» Innovent’s picankibart hits phase III plaque psoriasis endpoints
To read the full story,
subscribe
or
sign in
.
Innovent’s picankibart hits phase III plaque psoriasis endpoints
May 28, 2024
By
Tamra Sami
No Comments
Innovent Biologics Inc.’s picankibart (IBI-112) met all primary endpoints and key secondary endpoints in the phase III registrational Clear-1 trial in Chinese subjects with moderate to severe plaque psoriasis.
BioWorld
BioWorld Asia
Clinical
Dermatologic
Immune
Monoclonal antibody
Asia-Pacific
China
NMPA